Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

MyRisk: Efficacy and Safety Evaluation of Oral Akynzeo® in Patients Receiving MEC at High Risk of Developing CINV Based on a Prediction Tool: A Multinational and Multicenter Study

NCT04817189 is registered in ClinicalTrials.gov with Helsinn Healthcare SA as lead sponsor.

NCT NCT04817189
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04817189 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
MyRisk: Efficacy and Safety Evaluation of Oral Akynzeo® in Patients Receiving MEC at High Risk of Developing CINV Based on a Prediction Tool: A Multinational and Multicenter Study
Lead sponsor
Helsinn Healthcare SA
Phase
Phase 4
Overall status
Completed
Start date
February 1, 2021
Completion date
July 2, 2024
Enrollment
414 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

chemotherapy-induced nausea and vomiting